The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study
- Authors
- Lee, Eun Ji; Park, Soo Jin; Lee, Jeesun; Mun, Jaehee; Paik, Haerin; Seol, Aeran; Kim, Junhwan; Yim, Ga Won; Shim, Seung-Hyuk; Kim, Hee Seung; Chang, Suk-Joon
- Issue Date
- Jan-2022
- Publisher
- INT INST ANTICANCER RESEARCH
- Keywords
- Pressurized intraperitoneal aerosol chemotherapy; peritoneal metastasis; survey; clinical desire; prerequisite; cost
- Citation
- ANTICANCER RESEARCH, v.42, no.1, pp 363 - 371
- Pages
- 9
- Journal Title
- ANTICANCER RESEARCH
- Volume
- 42
- Number
- 1
- Start Page
- 363
- End Page
- 371
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74159
- DOI
- 10.21873/anticanres.15494
- ISSN
- 0250-7005
1791-7530
- Abstract
- Background/Aim: To evaluate the clinical desire for pressurized intraperitoneal aerosol chemotherapy (PIPAC) in South Korea. Patients and Methods: We performed an online survey on surgical oncologists between November and December 2019 using a questionnaire consisting of 20 questions. Results: A total of 164 respondents answered the questionnaire. Among those specialized in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma 41.7-50% preferred PIPAC for the curative treatment of primary diseases, whereas 32.7-33.3% majoring in colorectal and hepatobiliary cancers chose it for the palliative treatment of recurrent diseases. Furthermore, 66.795.2% considered PIPAC appropriate for the cancers they specialized in, and 76-78.7% expected a treatment response of more than 50% and considered grade 1 or 2 complications acceptable. Most respondents answered the reasonable costs to purchase and implement PIPAC once at between 1,000,000-5,000,000 South Korean Won (KRW). Conclusion: Most Korean surgical oncologists expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74159)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.